TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26829441

Group type: EXPERIMENTAL
Intervention: Insulin suppression of VLDL-TG secretion
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Insulin suppression of VLDL-TG oxidation
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Insulin suppression of VLDL-TG concentration
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Insulin suppression of VLDL particle size
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Insulin suppression of endogenous glucose production
Number of subjects: 27
Study: 26829444

Group type: COMPARATOR
Intervention: T2D
Number of subjects: 371

Group type: COMPARATOR
Intervention: T1D
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: T2D and T1D combined
Number of subjects: 371
Study: 26829928

Group type: EXPERIMENTAL
Intervention: Nutritional intakes, physical activity levels, and anthropometric measurements
Number of subjects: 9000
Study: 26830335

Group type: EXPERIMENTAL
Intervention: Influenza A/H1N1 infection (cases)
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Antibiotics adapted to sputum colonization (cases)
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Oseltamivir treatment (cases)
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Antibiotic treatments (cases)
Number of subjects: 415

Group type: COMPARATOR
Intervention: Antibiotic treatments (controls)
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Lung function (FEV1)
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Sputum colonization
Number of subjects: 415
Study: 26830930

Group type: EXPERIMENTAL
Intervention: Patient decision aid (PtDA) for PTSD
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Literature review of effective PTSD treatments
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Feedback from patients and providers on PtDA
Number of subjects: 19
Study: 26830967

Group type: EXPERIMENTAL
Intervention: Congenital TTP patients with renal insufficiency (n=13)
Number of subjects: 32
Study: 26831232

Group type: EXPERIMENTAL
Intervention: Tenofovir (TDF), Lamivudine (3TC), Efavirenz (EFV)
Number of subjects: 100
Study: 26831486

Group type: EXPERIMENTAL
Intervention: Educational interventions to promote colorectal cancer screening
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Fear of procedure and concern about taking a powerful laxative
Number of subjects: 102
Study: 26831652

Group type: EXPERIMENTAL
Intervention: Albuterol MDPI with integrated dose counter (2 inhalations/dose; 90 μg/inhalation) twice daily for up to 50 days
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Albuterol MDPI with integrated dose counter
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Albuterol MDPI
Number of subjects: 317
Study: 26831844

Group type: EXPERIMENTAL
Intervention: budesonide/formoterol (160/4.5 μg, one inhalation twice daily and as needed)
Number of subjects: 478
Study: 26832194

Group type: EXPERIMENTAL
Intervention: Tositumomab/Iodine-131 Tositumomab (TST/I-131 TST)
Number of subjects: 15
Study: 26832367

Group type: EXPERIMENTAL
Intervention: Serum 14-3-3η protein levels ≥0.50 ng/ml
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Elevated levels of 14-3-3η during follow-up
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Decreases of 14-3-3η levels by at least 0.76 ng/ml
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Baseline 14-3-3η ≥0.19 ng/ml
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Optimal baseline 14-3-3η levels defined by ROC curves at 0.50 ng/ml
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: 14-3-3η, CRP, age and Abs
Number of subjects: 331
Study: 26832753

Group type: EXPERIMENTAL
Intervention: Rifabutin at 150 mg once daily with non-boosted or ritonavir-boosted PIs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rifabutin at 300 mg every 3 days with boosted PI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rifabutin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Des-rifabutin
Number of subjects: 0
Study: 26833097

Group type: EXPERIMENTAL
Intervention: Systematic evaluation including bone imaging and blood laboratory testing
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Blood laboratory testing
Number of subjects: 54
Study: 26834058

Group type: EXPERIMENTAL
Intervention: Neratinib 240 mg orally once per day
Number of subjects: 40
Study: 26835133

Group type: EXPERIMENTAL
Intervention: Pirfenidone
Number of subjects: 1299
Study: 26835134

Group type: EXPERIMENTAL
Intervention: Usual care as defined by their physician
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Patient-reported outcome questionnaires
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Blood samples for cellular, genetic and transcriptomic analyses
Number of subjects: 300
Study: 26835148

Group type: EXPERIMENTAL
Intervention: Lupus anticoagulant (LAC) presence
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Definite antiphospholipid syndrome
Number of subjects: 44

Group type: COMPARATOR
Intervention: Systemic lupus erythematosus (SLE)
Number of subjects: 44
Study: 26835225

Group type: EXPERIMENTAL
Intervention: Afatinib 50 mg/day plus letrozole 2.5 mg/day
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Afatinib 40 mg/day plus letrozole 2.5 mg/day
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Afatinib 30 mg/day plus letrozole 2.5 mg/day
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Afatinib combined with letrozole
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 28
Study: 26835906

Group type: EXPERIMENTAL
Intervention: Biologicals treatment
Number of subjects: 84
Study: 26836193

Group type: EXPERIMENTAL
Intervention: T3D-959 (0.3 to 3.0 mg/kg/day) for 28 days
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: T3D-959 (0.5-1.0 μM) on frontal lobe slice cultures
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Lowest tested dose of T3D-959
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group (saline)
Number of subjects: 2
Study: 26836793

Group type: EXPERIMENTAL
Intervention: Dabigatran (150 mg twice daily)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (20 mg daily)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Apixaban (5 mg twice daily)
Number of subjects: 234
Study: 26836895

Group type: EXPERIMENTAL
Intervention: Middle-aged adults (age 50-64)
Number of subjects: 4097

Group type: COMPARATOR
Intervention: Older adults (age 65-80)
Number of subjects: 4097

Group type: EXPERIMENTAL
Intervention: Middle-aged adults (age 50-64) with dyspnea severity (modified Medical Research Council ≥ 2)
Number of subjects: 4097

Group type: COMPARATOR
Intervention: Older adults (age 65-80) with dyspnea severity (modified Medical Research Council ≥ 2)
Number of subjects: 4097

Group type: EXPERIMENTAL
Intervention: Participants in SPIROMICS study
Number of subjects: 4097
Study: 26836896

Group type: EXPERIMENTAL
Intervention: Lung ultrasound (LUS) findings of infection, subpleural consolidation, and dynamic arborescent/linear air bronchogram
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Two dynamic linear/arborescent air bronchograms
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: VPLUS-EAgram
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: VPLUS
Number of subjects: 99
Study: 26836938

Group type: EXPERIMENTAL
Intervention: Persistent depression group (n = 377)
Number of subjects: 1589

Group type: EXPERIMENTAL
Intervention: New onset depression group (n = 226)
Number of subjects: 1589

Group type: COMPARATOR
Intervention: Never depressed group (n = 869)
Number of subjects: 1589

Group type: EXPERIMENTAL
Intervention: Remittent depression group (n = 117)
Number of subjects: 1589
Study: 26837432

Group type: EXPERIMENTAL
Intervention: Patient Directed Activity Program (up to three additional 30-minute bouts of activities daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient Directed Activity Program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study: 26837440

Group type: EXPERIMENTAL
Intervention: NBS20/eltrapuldencel-T (dendritic cell-based vaccine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Targeted therapy and immunotherapy
Number of subjects: 0
Study: 26838019

Group type: EXPERIMENTAL
Intervention: Fosaprepitant 150 mg IV on days 3 and 5, 5HT3 receptor antagonist days 1-5, dexamethasone 20 mg days 1 and 2, 4 mg po bid days 6, 7, and 8
Number of subjects: 65
Study: 26838022

Group type: EXPERIMENTAL
Intervention: Spanish version of the PRO-CTCAE
Number of subjects: 109
Study: 26838587

Group type: EXPERIMENTAL
Intervention: Baseline CTA-SI-ASPECTS
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: NCCT-ASPECTS
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Recanalization
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: NIHSS at 24 hours
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Symptomatic intracranial hemorrhage
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Modified Rankin scale score
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Mortality at 90 days
Number of subjects: 110
Study: 26839391

Group type: EXPERIMENTAL
Intervention: Stent procedures with ST
Number of subjects: 604

Group type: COMPARATOR
Intervention: Stent procedures without ST
Number of subjects: 604

Group type: EXPERIMENTAL
Intervention: Self-expanding covered stent grafts
Number of subjects: 604

Group type: COMPARATOR
Intervention: No ST
Number of subjects: 604

Group type: EXPERIMENTAL
Intervention: Treatment of chronic total occlusion lesions
Number of subjects: 604

Group type: EXPERIMENTAL
Intervention: In-stent restenosis lesions
Number of subjects: 604
Study: 26839475

Group type: EXPERIMENTAL
Intervention: PNH patients with hemolysis (LDH ≥ 1.5 × ULN)
Number of subjects: 301

Group type: COMPARATOR
Intervention: PNH patients with LDH < 1.5 × ULN
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Thromboembolism (TE)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Renal impairment
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: PNH-cytopenia
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Combination of hemolysis and 1 or more clinical symptoms (abdominal pain, chest pain, dyspnea)
Number of subjects: 301
Study: 26839476

Group type: EXPERIMENTAL
Intervention: Dietary fiber-enriched cereal flakes (DC)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Conventional cereal flakes (CC)
Number of subjects: 13
Study: 26840420

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 282

Group type: COMPARATOR
Intervention: Parental anxiety reduction
Number of subjects: 282
Study: 26840494

Group type: EXPERIMENTAL
Intervention: Gadobutrol-Enhanced Breast MRI (CE-BMRI)
Number of subjects: 906

Group type: COMPARATOR
Intervention: Unenhanced Breast MRI
Number of subjects: 906

Group type: COMPARATOR
Intervention: Mammography alone
Number of subjects: 906
Study: 26841930

Group type: EXPERIMENTAL
Intervention: Ledipasvir/sofosbuvir fixed-dose combination tablet for 12 weeks
Number of subjects: 85
Study: 26842272

Group type: EXPERIMENTAL
Intervention: Low adiponectin maternal levels in first trimester
Number of subjects: 1034

Group type: EXPERIMENTAL
Intervention: Low vitamin D maternal levels in first trimester
Number of subjects: 1034

Group type: EXPERIMENTAL
Intervention: Maternal dysglycaemia during pregnancy
Number of subjects: 1034
Study: 26843003

Group type: EXPERIMENTAL
Intervention: Brain MRI scans
Number of subjects: 503
Study: 26843355

Group type: EXPERIMENTAL
Intervention: Endovascular therapy (EVT)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Bypass surgery
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Patch plasty
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: No vascular intervention
Number of subjects: 102
Study: 26843482

Group type: EXPERIMENTAL
Intervention: Non-vitamin K antagonist oral anticoagulants (NOACs) including dabigatran etexilate, rivaroxaban, apixaban, and edoxaban
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vitamin K antagonists (VKAs) including warfarin
Number of subjects: 0
Study: 26843484

Group type: EXPERIMENTAL
Intervention: GMCI + SOC
Number of subjects: 182

Group type: COMPARATOR
Intervention: SOC alone
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: GMCI + SOC (in gross total resection patients)
Number of subjects: 182

Group type: COMPARATOR
Intervention: SOC alone (in gross total resection patients)
Number of subjects: 182
Study: 26843560

Group type: EXPERIMENTAL
Intervention: Daclizumab high-yield process (DAC-HYP)
Number of subjects: 31
Study: 26844128

Group type: EXPERIMENTAL
Intervention: Wrist-worn monitor (Polar Active) with feedback
Number of subjects: 276
Study: 26844132

Group type: EXPERIMENTAL
Intervention: Promotional media condition
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Social network condition
Number of subjects: 217

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 217
Study: 26844166

Group type: EXPERIMENTAL
Intervention: Wellness Action Plan
Number of subjects: 181

Group type: COMPARATOR
Intervention: Standard diet and activity counseling
Number of subjects: 181
Study: 26844197

Group type: EXPERIMENTAL
Intervention: Expert system-based, print-delivered physical activity intervention
Number of subjects: 232

Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 232
Study: 26844269

Group type: EXPERIMENTAL
Intervention: EEG spectral power, coherence, phase lag, Pearson and partial correlations, and epileptiform activity during awake, slow wave sleep, and REM sleep states
Number of subjects: 137
Study: 26844275

Group type: EXPERIMENTAL
Intervention: RILA ≥ 12%
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: No adjuvant hormonotherapy
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: RILA < 12%
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: RILA ≥ 20%
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Increasing values of RILA
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: ROC curve analysis
Number of subjects: 502
Study: 26844278

Group type: EXPERIMENTAL
Intervention: Vitamin E δ-tocotrienol (VEDT) 200 to 3200 mg daily for 13 days before surgery and one dose on the day of surgery
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Vitamin E δ-tocotrienol (VEDT) 200 to 1600 mg daily for 2 weeks before pancreatic surgery
Number of subjects: 25
Study: 26844283

Group type: EXPERIMENTAL
Intervention: Stem Cell Educator (SCE) therapy
Number of subjects: 15
Study: 26844479

Group type: EXPERIMENTAL
Intervention: Desensitization regimen consisting of 2 doses of IVIG (2 g/kg), a single dose of rituximab (375 mg/m), and 4 doses of bortezomib (1.3 mg/m)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Desensitization regimen
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study: 26844757

Group type: EXPERIMENTAL
Intervention: doxylamine-pyridoxine
Number of subjects: 0
Study: 26845266

Group type: EXPERIMENTAL
Intervention: Cariprazine
Number of subjects: 1466

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1466
Study: 26845282

Group type: EXPERIMENTAL
Intervention: Risperidone (administered for 6 weeks)
Number of subjects: 25
Study: 26846118

Group type: EXPERIMENTAL
Intervention: Water Exchange (WE)
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Water Immersion (WI)
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Air/Carbon Dioxide Insufflation (AICD)
Number of subjects: 1200
Study: 26846166

Group type: EXPERIMENTAL
Intervention: Integrative medicine (IM) approach, non-standardized and personalized, multimodal
Number of subjects: 10000
Study: 26846377

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IL-4
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) in HDM murine model
Number of subjects: 0
Study: 26846895

Group type: EXPERIMENTAL
Intervention: HIV test proposed to each study participant
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Questionnaire including life-event interview
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Qualitative exploratory study
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matched control group of people without disabilities
Number of subjects: 0
Study: 26847010

Group type: EXPERIMENTAL
Intervention: DT gait measures combined with the digit span task
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: DT gait measures combined with the auditory Stroop task
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: DT gait measures combined with the mobile phone task
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: DT cognitive measures (digit span task)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: DT cognitive measures (auditory Stroop task)
Number of subjects: 62
Study: 26847118

Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated Zilver PTX stent
Number of subjects: 907
Study: 26847408

Group type: EXPERIMENTAL
Intervention: Exposure to higher air pressure and higher humidity
Number of subjects: 1370

Group type: EXPERIMENTAL
Intervention: Exposure to cat's allergens
Number of subjects: 1370

Group type: EXPERIMENTAL
Intervention: Presence of asthma and current ICS therapy
Number of subjects: 1370

Group type: EXPERIMENTAL
Intervention: ETC (exercise treadmill challenge) results
Number of subjects: 1370

Group type: EXPERIMENTAL
Intervention: Reported dyspnea/cough
Number of subjects: 1370

Group type: EXPERIMENTAL
Intervention: Bronchoconstriction induced during PE lesson
Number of subjects: 1370
Study: 26847436

Group type: COMPARATOR
Intervention: PEEP trial at 4 cmH2O
Number of subjects: 20

Group type: COMPARATOR
Intervention: PEEP trial at 12 cmH2O
Number of subjects: 20

Group type: COMPARATOR
Intervention: PEEP trial (4 and 12 cmH2O)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Airway pressures and tidal volume normalized to body weight
Number of subjects: 20
Study: 26848057

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (50 mg dose)
Number of subjects: 150
Study: 26849144

Group type: EXPERIMENTAL
Intervention: Clopidogrel (N = 59)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Prasugrel (N = 71)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Ticagrelor (N = 75)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Smoking resumption after cessation (T2)
Number of subjects: 205
Study: 26849202

Group type: EXPERIMENTAL
Intervention: High-frequency rTMS (10 Hz, 120% motor threshold, 3000 pulses applied to the dorsolateral prefrontal cortex, MRI guided)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: MRI-guided localization
Number of subjects: 10

Group type: COMPARATOR
Intervention: 5 cm rule and Beam F3 methods
Number of subjects: 10
Study: 26849853

Group type: EXPERIMENTAL
Intervention: R-CHOP or R-CVP followed by (90) Y-IT (15 MBq/kg, maximum 1200 MBq) preceded by two infusions of 250 mg/m(2) rituximab
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: R-CHOP or R-CVP followed by (90) Y-IT
Number of subjects: 52
Study: 26850111

Group type: EXPERIMENTAL
Intervention: Complementary and alternative medicine (CAM) treatment administered by Korean medicine doctors (KMDs)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Non-long term follow-up group (n=48)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Long term follow-up group (n=117)
Number of subjects: 165
Study: 26850512

Group type: EXPERIMENTAL
Intervention: Genomic plot method for estimating nondisplaceable fraction using baseline scans only.
Number of subjects: 7
Study: 26850626

Group type: EXPERIMENTAL
Intervention: Myocardial triglyceride content measured on magnetic resonance spectroscopy (1H-MRS) in patients with low LVEF (<50%)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Myocardial triglyceride content measured on magnetic resonance spectroscopy (1H-MRS) in patients with normal LVEF (≥50%)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Myocardial triglyceride content measured on magnetic resonance spectroscopy (1H-MRS) in controls
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Association of myocardial UFA/TG ratio with LV mass
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Association of myocardial UFA/TG ratio with LV end-diastolic volume (LVEDV)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Correlation of myocardial FA/TG ratio with LV mass
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Correlation of myocardial FA/TG ratio with LVEDV
Number of subjects: 50
Study: 26850678

Group type: EXPERIMENTAL
Intervention: KW-2450 40 mg/kg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: KW-2450 37.5 mg once daily continuously
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: KW-2450 50 mg/day
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: KW-2450
Number of subjects: 13
Study: 26850762

Group type: EXPERIMENTAL
Intervention: Genomic information with emotion induction (fear state)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genomic information with emotion induction (anger state)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genomic information with emotion induction (neutral state)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Behavioral information with emotion induction (fear state)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Behavioral information with emotion induction (anger state)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Behavioral information with emotion induction (neutral state)
Number of subjects: 0
Study: 26851029

Group type: EXPERIMENTAL
Intervention: BEZ235 400 mg bid
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: BEZ235 300 mg bid
Number of subjects: 31
Study: 26851813

Group type: EXPERIMENTAL
Intervention: Hand-held single-lead electrocardiogram (ECG) device (MyDiagnostick) used for screening during influenza vaccination.
Number of subjects: 3269